Glaxo's CEO Set to Highlight Cancer Ambitions With Key Drugs
- Three drugs may be launched within two years, Walmsley to say
- Drugmaker’s chief to speak at San Francisco conference Tuesday
This article is for subscribers only.
GlaxoSmithKline Plc Chief Executive Officer Emma Walmsley is moving quickly to rebuild the U.K. pharma giant’s position in cancer, following an agreement last month to buy drugmaker Tesaro Inc. for $5.1 billion.
In a presentation at a San Francisco conference Tuesday, Walmsley plans to discuss the potential for three key oncology treatments to hit the market within the next two years, including two from Tesaro, according to a person familiar with remarks she’s scheduled to give. Those drugs could start to help Glaxo’s sales growth outlook starting next year, said the person, who asked not to be identified because the information isn’t public.